Literature DB >> 3137053

Comparative in vitro activity of the new oral cephalosporin cefixime.

G W Counts1, L K Baugher, B K Ulness, D J Hamilton.   

Abstract

Cefixime was 8 to 10 times more active than cefaclor and augmentin against isolates of Escherichia coli, Klebsiella pneumoniae and Salmonella typhi, MIC90 values ranging from 0.06 to 0.25 micrograms/ml. However, none of these three drugs was particularly active against isolates of more resistant gram-negative bacilli such as Enterobacter, Serratia, Citrobacter, Acinetobacter, Providencia and Achromobacter spp. The lowest MIC values for gram-negative bacilli were seen with ciprofloxacin, except for isolates of Acinetobacter, where cotrimoxazole was the most active of the five drugs studied. Augmentin and ciprofloxacin exhibited the lowest MICs for isolates of streptococci and corynebacteria. Although cefixime may be among the most active oral beta-lactam drugs, it does not appear to be useful for treatment of infections caused by more resistant gram-negative bacilli.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3137053     DOI: 10.1007/bf01962357

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  7 in total

1.  An inocula replicating apparatus for routine testing of bacterial susceptibility to antibiotics.

Authors:  E STEERS; E L FOLTZ; B S GRAVES
Journal:  Antibiot Chemother (Northfield)       Date:  1959-05

2.  Comparison of in vitro antibacterial activity of three oral cephalosporins: cefaclor, cephalexin, and cephradine.

Authors:  M S Silver; G W Counts; D Zeleznik; M Turck
Journal:  Antimicrob Agents Chemother       Date:  1977-11       Impact factor: 5.191

3.  BMY 28100, a new oral cephalosporin.

Authors:  F Leitner; T A Pursiano; R E Buck; Y H Tsai; D R Chisholm; M Misiek; J V Desiderio; R E Kessler
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

4.  The pharmacokinetic and bactericidal characteristics of oral cefixime.

Authors:  D C Brittain; B E Scully; T Hirose; H C Neu
Journal:  Clin Pharmacol Ther       Date:  1985-11       Impact factor: 6.875

5.  Penetration of cefixime into fibrin clots and in vivo efficacy against Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus.

Authors:  M G Bergeron; A Turcotte
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

6.  In vitro activity of cefixime and six other agents against nosocomial pathogens of the Enterobacteriaceae family.

Authors:  M E Mulligan
Journal:  Infect Control       Date:  1987-06

7.  Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin.

Authors:  H C Neu; N X Chin; P Labthavikul
Journal:  Antimicrob Agents Chemother       Date:  1984-08       Impact factor: 5.191

  7 in total
  4 in total

1.  Biliary excretion of cefixime: assessment in patients provided with T-tube drainage.

Authors:  J F Westphal; F Jehl; M Schloegel; H Monteil; J M Brogard
Journal:  Antimicrob Agents Chemother       Date:  1993-07       Impact factor: 5.191

2.  Cefixime penetration in human renal parenchyma.

Authors:  A Leroy; B Oser; P Grise; G Humbert
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

Review 3.  Cefixime. A review of its antibacterial activity. Pharmacokinetic properties and therapeutic potential.

Authors:  R N Brogden; D M Campoli-Richards
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

4.  Chronic wound isolates and their minimum inhibitory concentrations against third generation cephalosporins at a tertiary hospital in Uganda.

Authors:  Khalim Wangoye; James Mwesigye; Martin Tungotyo; Silvano Twinomujuni Samba
Journal:  Sci Rep       Date:  2022-01-24       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.